Kopran Ltd Stock Analysis

BSE: 524280 | NSE: KOPRAN | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 29-Sep-2023 18:02
226.65 -0.05 (-0.02%)

DeciZen - Make an Informed Decision on Kopran

Overall Rating

1. Quality

2. Valuation


3. Price Trend

Kopran Price Chart

P/E Ratio (SA):
Market Cap:
1,092.7 Cr.
52-wk low:
52-wk high:
Bole Toh?

1. Is Kopran Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kopran Ltd is a below average quality company.

2. Is Kopran Ltd undervalued or overvalued?

The key valuation ratios of Kopran Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Kopran Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Kopran Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Kopran:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kopran Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 10.7%6.2%8.4%3.9%1.8%6.5%5.7%7.5%3.2%7.8%-
Value Creation Index -0.2-0.6-0.4-0.7-0.9-0.5-0.6-0.5-0.8-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 302326187182154197179223205273268
YoY Gr. Rt. %-7.8%-42.5%-3.1%-15.3%27.9%-8.8%24.3%-8.2%33.5%-
YoY Gr. Rt. %--63.8%80%-77.8%-96.8%15250%-14%54.2%-54.8%249.5%-
BVPS (₹) 3539.643.546.547.650.553.157.178.682.182.1
Adj Net Profit 16.76.412.
Cash Flow from Ops. 1.952.618.74.212.511.81048.8-37.816.9-
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -1.1%12.2%15.1%33.5%
Adj EPS 4.6%217.3%34.6%249.5%
Share Price 31.1% 42.4% 35.7% 43.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity %
Op. Profit Mgn % 14.19.713.39.64.711.813.113.57.510.47.9
Net Profit Mgn % 5.526.
Debt to Equity
Working Cap Days 2282212671882331862291872362310
Cash Conv. Cycle 55362254842845587830

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 7.00%

Sales growth is growing at healthy rate in last 3 years 15.06%

Net Profit is growing at healthy rate in last 3 years 34.55%

Sales growth is not so good in last 4 quarters at 9.21%

Latest Financials - Kopran Ltd.

Standalone Consolidated
TTM EPS (₹) 5.7 4.7
TTM Sales (₹ Cr.) 268 541
BVPS (₹.) 82.1 91.7
Reserves (₹ Cr.) 348 394
P/BV 2.76 2.45
PE 39.59 48.40
From the Market
52 Week Low / High (₹) 96.00 / 253.00
All Time Low / High (₹) 6.40 / 558.84
Market Cap (₹ Cr.) 1,093
Equity (₹ Cr.) 48.2
Face Value (₹) 10
Industry PE 42.8

Management X-Ray of Kopran :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Kopran

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Kopran Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Kopran on 29-Sep-2023 18:02 is : 226.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Sep-2023 18:02 the market cap of Kopran stood at ₹ 1,092.7.
The latest PE ratio of Kopran as of 29-Sep-2023 18:02 is 39.59.
The latest PB ratio of Kopran as of 29-Sep-2023 18:02 is 2.76
The 52-week high of Kopran is ₹ 253.0 and the 52-week low is ₹ 96.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Kopran is ₹ 267.7 ( Cr.) .

About Kopran Ltd

The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them.

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.

Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.

Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.

The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.

KRLL is a 100% subsidiary of Kopran Ltd.  KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.

Product range of the company includes:

Finished Dosage Forms

  • Antibiotics/antibacterials
  • Anti-malarial
  • Cadiovasculars
  • Pain management
  • Anthelminthics
  • Antiprotozoals
  • Antidiabetics
  • Gastrointestinals
  • Drug for erectile dysfuntion
  • Antiallergics
  • Respiratory/anti-asthmatics
  • Metered dose inhalers
  • Dry powder inhalers
  • Antiviral

Active Pharmaceutical Ingredients

  • Anti-hypertensives
  • Macrolides
  • Taste Masked
  • Cephalosporins 
  • Under Development
  • Others

Achievements/ recognition:

  • Kopran has a state of art manufacturing plants (Penicillin & General) approved by: -MCC (South Africa) -TGA, Australia and FDA, USA are in the pipeline

Future plans:

  • Brand Equity Development
  • Research for New Chemical Entities
  • Globalise its operations thus making Kopran a truly International Pharmaceutical Company.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now